Additionally, fibroblast growth factor 1 (FGF1) inhibitors have been studied in this context, as the upregulation of FGF1 has been implicated in resistance to BRAF and MEK inhibition, and its blockade may help to resensitize melanoma cells to targeted therapy. The gene discussed is BRAF; the disease is melanoma.